{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T07:00:08Z","timestamp":1762326008785,"version":"3.41.2"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Treatment resistant depression (TRD) affects approximately 10\u201330% of patients with major depressive disorder, and most patients with TRD do not respond to real-world treatments (RWT). Treatment with esketamine nasal spray (NS) plus a selective serotonin or serotonin norepinephrine reuptake inhibitor (SSRI\/SNRI) has significant long-term clinical benefit over RWT in patients with TRD. However, the impact on patient-reported function remains to be determined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The ICEBERG analysis was an indirect treatment comparison performed using data from two studies of patients with TRD: SUSTAIN-2 (esketamine NS; NCT02497287) and the European Observational TRD Cohort (EOTC; RWT; NCT03373253; clinicaltrials.gov). Here, patient\u2212reported functional remission, assessed using the Sheehan Disability Scale (SDS), was defined as SDS \u22646 at Month 6. Analyses were conducted using propensity score re\u2212weighting and multivariable models based on 18 covariates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At Month 6, the probability of functional remission in esketamine NS\u2212treated patients from SUSTAIN-2 (n=512) was 25.6% (95% confidence interval [CI] 21.8\u201329.4), while the adjusted probability for RWT patients from the EOTC (n=184) was 11.5% (95% CI 6.9\u201316.1; relative risk: 2.226 [95% CI 1.451\u20133.416]; p=0.0003). In the total combined population (N=696), patients who did not achieve clinical response or remission had a low probability of achieving functional remission (5.84% and 8.76%, respectively). However, for patients who did achieve clinical response or remission, the probability of achieving functional remission was greater (43.38% and 54.15%, respectively), although many still did not achieve this status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>For patients with TRD, esketamine NS had a significant functional benefit versus RWT after 6 months of treatment. Irrespective of treatment, achievement of clinical response or remission was insufficient to attain functional remission. Nevertheless, clinical remission increased the likelihood of achieving functional remission, further supporting an important role for clinical remission in for the path towards functional recovery.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2024.1459633","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T07:29:12Z","timestamp":1728286152000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission: results from the ICEBERG study"],"prefix":"10.3389","volume":"15","author":[{"given":"Albino J.","family":"Oliveira-Maia","sequence":"first","affiliation":[]},{"given":"Beno\u00eet","family":"Rive","sequence":"additional","affiliation":[]},{"given":"Yordan","family":"Godinov","sequence":"additional","affiliation":[]},{"given":"Siobh\u00e1n","family":"Mulhern-Haughey","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.03.073","article-title":"Real world evidence from a European cohort study of patients with treatment resistant depression: Treatment patterns and clinical outcomes","volume":"290","author":"Heerlein","year":"2021","journal-title":"J Affect Disord"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12888-019-2222-4","article-title":"The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study","volume":"19","author":"Jaffe","year":"2019","journal-title":"BMC Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S29716","article-title":"Treatment-resistant depression: therapeutic trends, challenges, and future directions","volume":"6","author":"Al-Harbi","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S198774","article-title":"Management of treatment-resistant depression: challenges and strategies","volume":"16","author":"Voineskos","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"volume-title":"Guideline on clinical investigation of medicinal products in the treatment of depression","year":"2013","key":"B6"},{"key":"B7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jad.2018.06.045","article-title":"The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature","volume":"242","author":"Johnston","year":"2019","journal-title":"J Affect Disord"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2015.17.2\/dionescu","article-title":"Pharmacological approaches to the challenge of treatment-resistant depression","volume":"17","author":"Ionescu","year":"2015","journal-title":"Dialogues Clin Neurosci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.11.004","article-title":"Real-world evidence from a European cohort study of patients with treatment resistant depression: healthcare resource utilization","volume":"298","author":"Heerlein","year":"2021","journal-title":"J Affect Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.11.003","article-title":"Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review","volume":"227","author":"Lee","year":"2018","journal-title":"J Affect Disord"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e00622","DOI":"10.1002\/brb3.622","article-title":"The effect of vortioxetine on overall patient functioning in patients with major depressive disorder","volume":"7","author":"Florea","year":"2017","journal-title":"Brain Behav"},{"key":"B12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/YIC.0b013e3282f2b4d6","article-title":"Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale","volume":"23","author":"Sheehan","year":"2008","journal-title":"Int Clin Psychopharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpsm.2022.06.002","article-title":"Depression and suicidality severity among TRD patients after 1-year under standard of care: Findings from the TRAL study, a multicenter, multinational, observational study in Latin America","volume":"16","author":"Caldieraro","year":"2022","journal-title":"Rev Psiquiatr\u00eda y Salud Ment"},{"key":"B14","unstructured":"Seroquel XR: summary of product characteristics 20192019"},{"key":"B15","unstructured":"Spravato EPAR product characteristics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"Am J Geriatr Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am J Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304145","article-title":"Esketamine nasal spray versus quetiapine for treatment-resistant depression","volume":"389","author":"Reif","year":"2023","journal-title":"New Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1250980","article-title":"ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in general psychiatry","volume":"14","author":"Oliveira-Maia","year":"2023","journal-title":"Front Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1250987","article-title":"Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study","volume":"14","author":"Oliveira-Maia","year":"2023","journal-title":"Front Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.11.124","article-title":"Real-world evidence from a European cohort study of patients with treatment resistant depression: Baseline patient characteristics","volume":"283","author":"Heerlein","year":"2021","journal-title":"J Affect Disord"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.915689","article-title":"Remission of symptoms is not equal to functional recovery: Psychosocial functioning impairment in major depression","volume":"13","author":"Yang","year":"2022","journal-title":"Front Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.201600094","article-title":"Propensity scores based methods for estimating average treatment effect and average treatment effect among treated: A comparative study","volume":"59","author":"Abdia","year":"2017","journal-title":"Biom J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1166","article-title":"The place of memantine in the treatment of Alzheimer\u2019s disease: a number needed to treat analysis","volume":"19","author":"Livingston","year":"2004","journal-title":"Int J Geriatr Psychiatry"},{"volume-title":"NICE DSU Technical Support Document 17: The use of observational data to inform estimates of treatment effectiveness for Technology Appraisal: Methods for comparative individual patient data","year":"2015","author":"Faria","key":"B28"},{"volume-title":"Choices in methods for economic evaluation","year":"2020","key":"B29"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1055\/a-1237-4011","article-title":"Manual for methods and use of routine practice data for knowledge generation","volume":"82","author":"Klinkhammer-Schalke","year":"2020","journal-title":"Gesundheitswesen"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials\u2013extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Making"},{"volume-title":"Developing NICE guidelines: the manual","year":"2023","key":"B33"},{"key":"B34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.euroneuro.2023.04.011","article-title":"Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study","volume":"74","author":"Chiappini","year":"2023","journal-title":"Eur Neuropsychopharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.13296","article-title":"Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression","volume":"25","author":"Martinotti","year":"2023","journal-title":"Bipolar Disord"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2024.1459633\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T07:29:18Z","timestamp":1728286158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2024.1459633\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":35,"alternative-id":["10.3389\/fpsyt.2024.1459633"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2024.1459633","relation":{},"ISSN":["1664-0640"],"issn-type":[{"type":"electronic","value":"1664-0640"}],"subject":[],"published":{"date-parts":[[2024,10,7]]},"article-number":"1459633"}}